Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice

Cara J. Westmark, Pamela R. Westmark, Kenneth J. O'Riordan, Brian C. Ray, Crystal M. Hervey, M. Shahriar Salamat, Sara H. Abozeid, Kelsey M. Stein, Levi A. Stodola, Michael Tranfaglia, Corinna Burger, Elizabeth M. Berry-Kravis, James S. Malter

Research output: Contribution to journalArticle

76 Citations (Scopus)

Abstract

Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39-43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1 KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1 KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ 1-42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.

Original languageEnglish (US)
Article numbere26549
JournalPLoS One
Volume6
Issue number10
DOIs
StatePublished - 2011

Fingerprint

Fragile X Syndrome
Amyloid beta-Protein Precursor
amyloid
Phenotype
phenotype
Brain
mice
Alzheimer disease
Fragile X Mental Retardation Protein
Plasmas
Alzheimer Disease
Metabotropic Glutamate Receptors
proteins
Biomarkers
Down syndrome
brain
Application programs
Amyloid
therapeutics
disease diagnosis

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Westmark, C. J., Westmark, P. R., O'Riordan, K. J., Ray, B. C., Hervey, C. M., Salamat, M. S., ... Malter, J. S. (2011). Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice. PLoS One, 6(10), [e26549]. https://doi.org/10.1371/journal.pone.0026549

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice. / Westmark, Cara J.; Westmark, Pamela R.; O'Riordan, Kenneth J.; Ray, Brian C.; Hervey, Crystal M.; Salamat, M. Shahriar; Abozeid, Sara H.; Stein, Kelsey M.; Stodola, Levi A.; Tranfaglia, Michael; Burger, Corinna; Berry-Kravis, Elizabeth M.; Malter, James S.

In: PLoS One, Vol. 6, No. 10, e26549, 2011.

Research output: Contribution to journalArticle

Westmark, CJ, Westmark, PR, O'Riordan, KJ, Ray, BC, Hervey, CM, Salamat, MS, Abozeid, SH, Stein, KM, Stodola, LA, Tranfaglia, M, Burger, C, Berry-Kravis, EM & Malter, JS 2011, 'Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice', PLoS One, vol. 6, no. 10, e26549. https://doi.org/10.1371/journal.pone.0026549
Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS et al. Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice. PLoS One. 2011;6(10). e26549. https://doi.org/10.1371/journal.pone.0026549
Westmark, Cara J. ; Westmark, Pamela R. ; O'Riordan, Kenneth J. ; Ray, Brian C. ; Hervey, Crystal M. ; Salamat, M. Shahriar ; Abozeid, Sara H. ; Stein, Kelsey M. ; Stodola, Levi A. ; Tranfaglia, Michael ; Burger, Corinna ; Berry-Kravis, Elizabeth M. ; Malter, James S. / Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice. In: PLoS One. 2011 ; Vol. 6, No. 10.
@article{7fa9dc56d91144b5af13e5fd9a0f0061,
title = "Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice",
abstract = "Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39-43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1 KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1 KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ 1-42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.",
author = "Westmark, {Cara J.} and Westmark, {Pamela R.} and O'Riordan, {Kenneth J.} and Ray, {Brian C.} and Hervey, {Crystal M.} and Salamat, {M. Shahriar} and Abozeid, {Sara H.} and Stein, {Kelsey M.} and Stodola, {Levi A.} and Michael Tranfaglia and Corinna Burger and Berry-Kravis, {Elizabeth M.} and Malter, {James S.}",
year = "2011",
doi = "10.1371/journal.pone.0026549",
language = "English (US)",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1 KO mice

AU - Westmark, Cara J.

AU - Westmark, Pamela R.

AU - O'Riordan, Kenneth J.

AU - Ray, Brian C.

AU - Hervey, Crystal M.

AU - Salamat, M. Shahriar

AU - Abozeid, Sara H.

AU - Stein, Kelsey M.

AU - Stodola, Levi A.

AU - Tranfaglia, Michael

AU - Burger, Corinna

AU - Berry-Kravis, Elizabeth M.

AU - Malter, James S.

PY - 2011

Y1 - 2011

N2 - Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39-43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1 KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1 KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ 1-42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.

AB - Fragile X syndrome (FXS) is the most common form of inherited intellectual disability and the leading known genetic cause of autism. Fragile X mental retardation protein (FMRP), which is absent or expressed at substantially reduced levels in FXS, binds to and controls the postsynaptic translation of amyloid β-protein precursor (AβPP) mRNA. Cleavage of AβPP can produce β-amyloid (Aβ), a 39-43 amino acid peptide mis-expressed in Alzheimer's disease (AD) and Down syndrome (DS). Aβ is over-expressed in the brain of Fmr1 KO mice, suggesting a pathogenic role in FXS. To determine if genetic reduction of AβPP/Aβ rescues characteristic FXS phenotypes, we assessed audiogenic seizures (AGS), anxiety, the ratio of mature versus immature dendritic spines and metabotropic glutamate receptor (mGluR)-mediated long-term depression (LTD) in Fmr1 KO mice after removal of one App allele. All of these phenotypes were partially or completely reverted to normal. Plasma Aβ 1-42 was significantly reduced in full-mutation FXS males compared to age-matched controls while cortical and hippocampal levels were somewhat increased, suggesting that Aβ is sequestered in the brain. Evolving therapies directed at reducing Aβ in AD may be applicable to FXS and Aβ may serve as a plasma-based biomarker to facilitate disease diagnosis or assess therapeutic efficacy.

UR - http://www.scopus.com/inward/record.url?scp=80055044964&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80055044964&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0026549

DO - 10.1371/journal.pone.0026549

M3 - Article

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

M1 - e26549

ER -